Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-2 gene-transduced allogeneic neuroblastoma cells
- Development stage
- Unknown
- Lead developer
- St. Jude Children's Research Hospital
- Modality
- Cell Therapies, Gene Therapies, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
IL-2 gene-transduced allogeneic neuroblastoma cells is an experimental cell-based immunotherapy developed by St. Jude Children's Research Hospital for the treatment of relapsed or refractory neuroblastoma. The therapy consists of allogeneic (donor-derived) neuroblastoma tumor cells that have been genetically modified using retroviral gene transfer to express and secrete human interleukin-2 (IL-2). Functioning as a cancer vaccine, the IL-2-secreting tumor cells are designed to stimulate a potent anti-tumor immune response, particularly by enhancing the activity of cytotoxic T lymphocytes and natural killer cells against neuroblastoma-specific antigens. This biologic therapy was evaluated in Phase I clinical trials where it was administered via subcutaneous injection to induce a local, polyclonal T-cell infiltrate and systemic anti-tumor immunity.
- Other names
- IL-2 gene-modified allogeneic neuroblastoma cellsIL2 gene-modified allogeneic neuroblastoma cellsIL 2 gene-modified allogeneic neuroblastoma cellsInterleukin-2-transduced neuroblastoma vaccineInterleukin2-transduced neuroblastoma vaccineInterleukin 2-transduced neuroblastoma vaccineIL-2 secreting allogeneic neuroblastoma cellsIL2 secreting allogeneic neuroblastoma cellsIL 2 secreting allogeneic neuroblastoma cells
Beyond the preview
Go deeper on IL-2 gene-transduced allogeneic neuroblastoma cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-2 gene-transduced allogeneic neuroblastoma cells.